{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T02:53:31Z","timestamp":1791687211651,"version":"4.3.4"},"reference-count":20,"publisher":"Public Library of Science (PLoS)","issue":"3","license":[{"start":{"date-parts":[[2023,3,31]],"date-time":"2023-03-31T00:00:00Z","timestamp":1680220800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"British Columbia Lung Foundation","award":["F21-00659"],"award-info":[{"award-number":["F21-00659"]}]},{"name":"Foundation Partners","award":["unrestricted educational grants"],"award-info":[{"award-number":["unrestricted educational grants"]}]},{"DOI":"10.13039\/100008349","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","award":["20R23666"],"award-info":[{"award-number":["20R23666"]}],"id":[{"id":"10.13039\/100008349","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Roche Products, Pty. Limited","award":["unrestricted educational grant"],"award-info":[{"award-number":["unrestricted educational grant"]}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:sec id=\"sec001\">\n<jats:title>Objectives<\/jats:title>\n<jats:p>Fibrotic interstitial lung disease (ILD) includes a large group of conditions that lead to scarring of the lungs. The lack of available 5-level EuroQol 5D (EQ5D) data has limited the ability to conduct economic evaluations in ILD. The purpose of this study was to develop and validate a mapping algorithm that predicts EQ5D utilities from commonly collected pulmonary function measurements (forced vital capacity [FVC] and diffusing capacity of the lung for carbon monoxide [DLCO]) in fibrotic ILDs.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec002\">\n<jats:title>Methods<\/jats:title>\n<jats:p>EQ5D utility and pulmonary function measurements from the Canadian Registry for Pulmonary Fibrosis were included. Ordinary least squares (OLS), beta regression, two-part, and tobit models were used to map EQ5D utilities from FVC or DLCO. Model performance was assessed by comparing the predicted and observed utilities. Subgroup analyses were also conducted to test how well models performed across different patient characteristics. The models were then externally validated in the Australian Idiopathic Pulmonary Fibrosis Registry.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec003\">\n<jats:title>Results<\/jats:title>\n<jats:p>The OLS model performed as well as other more complex models (root mean squared error: 0.17 for FVC and 0.16 for DLCO). As with the other models, the OLS algorithm performed well across the different subgroups (except for EQ5D utilities &lt; 0.5) and in the external validation cohort.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec004\">\n<jats:title>Conclusion<\/jats:title>\n<jats:p>We developed a mapping algorithm that predicts EQ5D utilities from FVC and DLCO, with the intent that this algorithm can be applied to clinical trial populations and real-world cohorts that have not prioritized collection of health-related utilities. The mapping algorithm can be used in future economic evaluations of potential ILD therapies.<\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pone.0283110","type":"journal-article","created":{"date-parts":[[2023,3,31]],"date-time":"2023-03-31T17:48:35Z","timestamp":1680284915000},"page":"e0283110","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":1,"title":["Mapping EQ5D utilities from forced vital capacity and diffusing capacity in fibrotic interstitial lung disease"],"prefix":"10.1371","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4910-1948","authenticated-orcid":true,"given":"Alyson W.","family":"Wong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiying","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingrid A.","family":"Cox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jolene H.","family":"Fisher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nasreen","family":"Khalil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerri A.","family":"Johannson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronica","family":"Marcoux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah","family":"Assayag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helene","family":"Manganas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Kolb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J.","family":"Palmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"de Graaff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E. Haydn","family":"Walters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Hopkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Zappala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole S.","family":"Goh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuben","family":"Moodley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vidya","family":"Navaratnam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamera J.","family":"Corte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher J.","family":"Ryerson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2023,3,31]]},"reference":[{"issue":"5","key":"pone.0283110.ref001","doi-asserted-by":"crossref","first-page":"e44","DOI":"10.1164\/rccm.201807-1255ST","article-title":"Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS\/ERS\/JRS\/ALAT Clinical Practice Guideline","volume":"198","author":"G Raghu","year":"2018","journal-title":"Am J Respir Crit Care Med"},{"key":"pone.0283110.ref002","doi-asserted-by":"crossref","first-page":"483","DOI":"10.2147\/CLEP.S54815","article-title":"Epidemiology of idiopathic pulmonary fibrosis.","volume":"5","author":"B Ley","year":"2013","journal-title":"Clin Epidemiol."},{"issue":"18","key":"pone.0283110.ref003","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1056\/NEJMoa1908681","article-title":"Nintedanib in Progressive Fibrosing Interstitial Lung Diseases","volume":"381","author":"KR Flaherty","year":"2019","journal-title":"N Engl J Med"},{"issue":"2","key":"pone.0283110.ref004","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/S2213-2600(19)30341-8","article-title":"Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trial.","volume":"8","author":"TM Maher","year":"2020","journal-title":"Lancet Respir Med."},{"key":"pone.0283110.ref005","unstructured":"EuroQol. EuroQoL instruments [Available from: https:\/\/euroqol.org\/eq-5d-instruments\/.]"},{"issue":"1","key":"pone.0283110.ref006","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1097\/MLR.0000000000000447","article-title":"A Time Trade-off-derived Value Set of the EQ-5D-5L for Canada.","volume":"54","author":"F Xie","year":"2016","journal-title":"Med Care."},{"key":"pone.0283110.ref007","doi-asserted-by":"crossref","DOI":"10.1007\/978-3-030-47622-9","author":"N Devlin","year":"2020","journal-title":"Methods for Analysing and Reporting EQ-5D Data"},{"issue":"1","key":"pone.0283110.ref008","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s40273-018-0701-y","article-title":"The Impact of Moving from EQ-5D-3L to -5L in NICE Technology Appraisals.","volume":"37","author":"B Pennington","year":"2019","journal-title":"Pharmacoeconomics."},{"key":"pone.0283110.ref009","doi-asserted-by":"crossref","first-page":"3562923","DOI":"10.1155\/2016\/3562923","article-title":"The Canadian Registry for Pulmonary Fibrosis: Design and Rationale of a National Pulmonary Fibrosis Registry.","volume":"2016","author":"CJ Ryerson","year":"2016","journal-title":"Can Respir J."},{"issue":"2","key":"pone.0283110.ref010","article-title":"Baseline characteristics of idiopathic pulmonary fibrosis: analysis from the Australian Idiopathic Pulmonary Fibrosis Registry","volume":"49","author":"HE Jo","year":"2017","journal-title":"Eur Respir J"},{"key":"pone.0283110.ref011","first-page":"391","article-title":"Change in FVC and survival in chronic fibrotic hypersensitivity pneumonitis.","author":"A Gimenez","journal-title":"Thorax. 73. England2018"},{"issue":"3","key":"pone.0283110.ref012","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1111\/resp.14204","article-title":"Short-term lung function changes predict mortality in patients with fibrotic hypersensitivity pneumonitis","volume":"27","author":"C Macaluso","year":"2022","journal-title":"Respirology"},{"issue":"3","key":"pone.0283110.ref013","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1002\/art.39971","article-title":"Progressive Decline of Lung Function in Rheumatoid Arthritis-Associated Interstitial Lung Disease.","volume":"69","author":"JA Zamora-Legoff","year":"2017","journal-title":"Arthritis Rheumatol"},{"issue":"6","key":"pone.0283110.ref014","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1183\/09031936.00080312","article-title":"Multi-ethnic reference values for spirometry for the 3-95-yr age range: the global lung function 2012 equations","volume":"40","author":"PH Quanjer","year":"2012","journal-title":"Eur Respir J"},{"issue":"4","key":"pone.0283110.ref015","doi-asserted-by":"crossref","first-page":"e0249123","DOI":"10.1371\/journal.pone.0249123","article-title":"Mapping expanded prostate cancer index composite to EQ5D utilities to inform economic evaluations in prostate cancer: Secondary analysis of NRG\/RTOG 0415.","volume":"16","author":"R Khairnar","year":"2021","journal-title":"PLoS One."},{"issue":"1","key":"pone.0283110.ref016","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1186\/s12955-019-1148-3","article-title":"Mapping analysis to estimate EQ-5D utility values using the COPD assessment test in Korea.","volume":"17","author":"J Lim","year":"2019","journal-title":"Health Qual Life Outcomes"},{"issue":"2","key":"pone.0283110.ref017","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.jval.2010.09.011","article-title":"Predicting EQ-5D values using the SGRQ.","volume":"14","author":"HJ Starkie","year":"2011","journal-title":"Value Health."},{"key":"pone.0283110.ref018","article-title":"Deriving utility weights for the EQ-5D-5L using a discrete choice experiment","author":"R Norman","year":"2012","journal-title":"CHERE Working Paper"},{"issue":"1","key":"pone.0283110.ref019","doi-asserted-by":"crossref","first-page":"1626171","DOI":"10.1080\/20016689.2019.1626171","article-title":"Cost-effectiveness of pirfenidone compared to all available strategies for the treatment of idiopathic pulmonary fibrosis in France.","volume":"7","author":"E Clay","year":"2019","journal-title":"J Mark Access Health Policy"},{"issue":"3","key":"pone.0283110.ref020","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/s40258-019-00467-6","article-title":"An Updated Systematic Review of Studies Mapping (or Cross-Walking) Measures of Health-Related Quality of Life to Generic Preference-Based Measures to Generate Utility Values.","volume":"17","author":"C Mukuria","year":"2019","journal-title":"Appl Health Econ Health Policy."}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0283110","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,31]],"date-time":"2023-03-31T17:48:59Z","timestamp":1680284939000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0283110"}},"subtitle":[],"editor":[{"given":"Bharat Bhushan","family":"Sharma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2023,3,31]]},"references-count":20,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2023,3,31]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0283110","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,31]]}}}